SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

Rhea-AI Summary

SRX Global (NYSE American: SRXH) announced it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), described as a late clinical-stage biopharmaceutical company developing nose-to-brain intranasal product candidates, called pherines, to address neurocircuitry involved in neuroscience indications.

According to SRX Global, it views Vistagen shares as undervalued and is open to constructive engagement with Vistagen’s leadership team and Board of Directors to discuss ideas for unlocking shareholder value. SRX Global describes itself as an AI-driven investment platform that uses proprietary technology, data analytics, and disciplined capital allocation to invest in high-conviction operating companies, strategic assets, and technology-enabled opportunities across multiple sectors.

Positive

• SRX Global acquires stake in Vistagen Therapeutics, adding a late clinical-stage neuroscience company to its investment portfolio

Negative

• None.

Market Context

The acquisition-tagged record averaged a 4.37% move across four events. The Vistagen stake announcem...

Analysis

The acquisition-tagged record averaged a 4.37% move across four events. The Vistagen stake announcement adds no disclosed stake size or transaction terms; the prior negative acquisition reaction remains a relevant risk.

Key Figures

Announcement date: Aug. 04, 2026

1 metrics

Announcement date Aug. 04, 2026 Article publication date

Previous Acquisition Reports

4 past events · Latest: Jun 08 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 08	Stake acquisition	Positive	+3.3%	SRx acquired 4.99% of Smartkem through a shelf takedown and private placement.
Apr 16	Portfolio acquisition	Positive	+6.4%	SRx acquired Compass shares and increased its investment in Opendoor Technologies.
Dec 16	Definitive acquisition agreement	Positive	+23.8%	SRx agreed to acquire EMJX subject to shareholder approval and customary closing conditions.
Aug 18	Asset acquisition proposal	Positive	-16.0%	SRx signed a non-binding letter of intent to acquire Royal Uranium assets.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Three of four acquisition-tagged events had positive 24-hour reactions, while the non-binding acquisition proposal had a negative reaction.

Key Terms

intranasal

1 terms

intranasal medical

"a new class of intranasal product candidates called pherines"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines.

The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Directors to discuss ideas on how to unlock shareholder value.

About SRX Global Inc.

SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

Company Contact

SRX Global
Kent Cunningham, Chief Executive Officer

Investor Relations Contact

KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
srx@kcsa.com

FAQ

What did SRX Global (SRXH) announce about Vistagen Therapeutics (VTGN) on August 4, 2026?

SRX Global announced it acquired a stake in Vistagen Therapeutics. According to SRX Global, Vistagen is a late clinical-stage biopharmaceutical company focused on nose-to-brain intranasal pherine product candidates in neuroscience, and SRX Global views Vistagen shares as undervalued.

What type of company is Vistagen Therapeutics (NASDAQ: VTGN) that SRX Global invested in?

Vistagen Therapeutics is described as a late clinical-stage biopharmaceutical company. According to SRX Global, Vistagen is pioneering neuroscience using nose-to-brain neurocircuitry and developing a new class of intranasal product candidates called pherines aimed at addressing neurological and psychiatric conditions.

Why does SRX Global (SRXH) consider Vistagen Therapeutics (VTGN) shares undervalued?

SRX Global stated that it views Vistagen shares as undervalued, but did not provide valuation details. According to SRX Global, it welcomes constructive engagement with Vistagen’s leadership and Board to discuss potential ideas for unlocking shareholder value over the long term.

Did SRX Global disclose the size of its stake in Vistagen Therapeutics (VTGN)?

SRX Global did not disclose the size or purchase price of its Vistagen stake. According to SRX Global, the announcement only confirms that a stake was acquired and emphasizes its investment view and interest in constructive engagement with Vistagen’s leadership and Board.

How does the Vistagen Therapeutics investment fit SRX Global’s AI-driven strategy (SRXH)?

The Vistagen stake aligns with SRX Global’s focus on high-conviction operating companies and strategic assets. According to SRX Global, its AI-driven platform uses proprietary technology and data analytics to identify and manage such investments across multiple sectors, including technology-enabled opportunities.

Is SRX Global planning activist involvement with Vistagen Therapeutics (VTGN)?

SRX Global did not describe its involvement as activist in the announcement. According to SRX Global, it “welcomes constructive engagement” with Vistagen’s leadership and Board to discuss ideas that could help unlock shareholder value, without outlining any specific governance or strategic proposals.